# LEADOPTIK

Source: https://onco.cc/companies/leadoptik/  
OnCo record `leadoptik` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LEADOPTIK is a California company making an optical imaging tool that shows doctors in real time whether a biopsy needle is in a small lung nodule. Its aim is earlier lung cancer diagnosis.

## Summary

Leadoptik Inc., of San Jose, California, states its mission as improving patient lives through early lung cancer detection. Its flagship Last Inch Assessment (LIA) technology provides real-time microstructure imaging for pulmonary imaging and biopsy; a clinical adviser quoted on its website says the company is preparing for its FDA submission. In fiscal year 2026 NCI awarded it USD 1,477,882 under SBIR grant 1R44CA314574-01 (Optical Precision Targeting for Informed Cancer biopsy), whose abstract addresses the low diagnostic yield of radial endobronchial ultrasound for peripheral lung nodules under 20 mm.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Leadoptik Inc.; LEADOPTIK INC.
- HQ: San Jose, CA
- Type: devices
- Website: https://leadoptik.com/

## Notes

- Founding year and regulatory status not stated on the website. Read on leadoptik.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://leadoptik.com/
- NIH RePORTER: award 1R44CA314574-01: https://reporter.nih.gov/project-details/11405793

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- fronts: [Devices & Physical Therapies](https://onco.cc/fronts/devices/), [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Optical & fluorescence imaging](https://onco.cc/technologies/optical-imaging/)
- drugs: [Last Inch Assessment (LIA)](https://onco.cc/drugs/leadoptik-last-inch-assessment/)

---
JSON: https://onco.cc/api/v1/entities/leadoptik.json